Drawing for LUNGCLEAR

USPTO serial 79366536

LUNGCLEAR

Reviewed by CopyMark Law Group

Reg. 7477128Status 700Registered
Filing date
Status date
Registration date
Aug 20, 2024
Examiner
CANTOR, JILLIAN REDDING
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LUNGCLEAR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joseph G. Chu

Joseph G. Chu JCIP155 N Lake Avenue, Suite 800Pasadena, CA 91101United States

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic preparations for medical and veterinary use or purposes; Medical diagnostic reactants for medical and veterinary diagnosis of diseases; diagnostic preparations for medical use for sale in kit form; diagnostic preparations for medical purposes; Biological indicators for medical diagnosis, namely, for detecting and diagnosing cancer; veterinary diagnostic reagents; Diagnostic reagents in kit form for conducting molecular biology assays for medical and veterinary purposes; Diagnostic reagents for medical and veterinary purposes; Diagnostic reagents for use in diagnostic tests for medical and veterinary purposes; pharmaceutical preparations for the treatment of disorders of the metabolic system; medical diagnostic reagents for testing of body fluids; Medical diagnostic assays that test for genetic anomalies for medical use; Diagnostic preparations for medical use; Biochemical preparations for diagnostic use for detecting and diagnosing cancer; Diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use in the medical field; Test reagents for medical diagnosis, namely, disease testing; diagnostic biomarker reagents for medical purposes; Chemical preparations for diagnostic medical purposes, namely, for detecting and diagnosing cancer; Chemical preparations for use in medical diagnostics, namely, nucleic acid analysis; Chemical preparations for detecting genetic and epigenetic predispositions for medical purposes; Medical diagnostic reagents for analysis of body fluids; Synthetic deoxyribonucleic acid and synthetic ribonucleic acid for medical use, namely, for detecting and diagnosing cancer; nucleic acid amplification reagents for medical useACTIVE—
010Medical diagnostic apparatus for detecting and diagnosing cancer; Medical diagnostic instruments for analysis of body fluids; Biomedical testing apparatus for RNA, DNA and protein biomarkers testing; Medical diagnostics instruments in the nature of apparatus for testing RNA, DNA and protein biomarkers; medical instruments for infectious disease testing; Medical diagnostic testing apparatus for sale in kit form for testing RNA, DNA and protein biomarkers for diagnosing and detecting cancer; Medical diagnostic apparatus for testing RNA, DNA and protein biomarkers for diagnosing and detecting cancer; Diagnostic in-vitro diagnostic testing apparatus for medical use for diagnosing and detecting cancer; Medical diagnostic testing apparatus for use in molecular biology procedures, namely, testing DNA, RNA and protein biomarkers for diagnosing and detecting cancer; Diagnostic apparatus for blood tests for medical useACTIVE—
044Medical diagnostic services, namely, testing and analysis; medical testing services relating to the diagnosis and treatment of disease; medical analysis services for the diagnosis of cancer; Medical services, namely, nucleic acid analysis for cancer diagnosis and prognosis; performing diagnosis of diseases; medical services for the diagnosis of conditions of the human body; genetic testing of animals for diagnostic or treatment purposes; medical laboratory services related to the treatment of patients; Medical advisory services in the field of oncological diseases; medical analysis for the diagnosis and treatment of persons; Medical services, namely, health risk assessment surveys; health-care services for treating and detecting cancer; genetic testing for medical purposes; Medical services, namely, nucleic acid screening for medical purposes; Medical analysis services for diagnosing and detecting cancer; medical screening; Health screening services in the field of cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 1, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 10, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 10, 2025FIMPFINAL DISPOSITION PROCESSED—
Nov 20, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 20, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 20, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 4, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 4, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 15, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 30, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 26, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 26, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 26, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 22, 2023RFNTREFUSAL PROCESSED BY IB—
Oct 27, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 27, 2023RFRRREFUSAL PROCESSED BY MPU—
Oct 20, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 19, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 17, 2023DOCKASSIGNED TO EXAMINER—
Apr 7, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 3, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 31, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance